Here are 23 recent drug shortages and discontinuations, according to the FDA’s drug supply databases:
Discontinued
- Ampicillin sodium injection: Multiple private-label strengths were discontinued Dec. 8.
- Calcitriol capsule: The 0.25-microgram and 0.5-microgram strengths were discontinued Dec. 4 as a business decision.
- Sodium chloride 0.9% injection: Several presentations, including ADD-Vantage containers, were discontinued Dec. 3.
- Posaconazole injection: The 18-mg/mL dose of Noxafil was discontinued Dec. 2.
- Nilutamide tablet: All 150-milligram presentations of Nilandron were discontinued Dec. 1.
- Phenoxybenzamine hydrochloride capsule: All 10-milligram presentations of Dibenzyline were discontinued Dec. 1.
In shortage
- Amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate tablet
- Azacitidine injection
- Carboplatin injection
- Clindamycin phosphate injection
- Furosemide injection
- Hydromorphone hydrochloride injection
- Ketorolac tromethamine injection
- Lisdexamfetamine dimesylate capsule
- Methotrexate sodium injection
- Methylphenidate hydrochloride extended-release tablet
- Nitroglycerin injection
- Rocuronium bromide injection
- Streptozocin powder for solution
- Parathyroid hormone injection
- Remifentanil hydrochloride injection
- Sodium bicarbonate injection
- Sterile water injection
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
